Perez-Calahorra S, et al. Behavioral cardiovascular risk factors and prevalence of diabetes in subjects with familial hypercholesterolemia. Eur J Prev Cardiol 2020; 27: 1649–1660.
2.
BarterPJRyeKATardifJC, et al.Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation2011; 124: 555–562.
3.
SattarNPreissDMurrayHM, et al.Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet2010; 375: 735–742.
4.
FerenceBARobinsonJGBrookRD, et al.Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med2016; 375: 2144–2153.
5.
BesselingJKasteleinJJDefescheJC, et al.Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA2015; 313: 1029–1036.
6.
XuHRyanKAJaworekTJ, et al.Familial hypercholesterolemia and type 2 diabetes in the Old Order Amish. Diabetes2017; 66: 2054–2058.
7.
ClimentEPerez-CalahorraSMarco-BenediV, et al.Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia. Sci Rep2017; 7: 5596–5596.
8.
CannonCPBlazingMAGiuglianoRP, et al.Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med2015; 372: 2387–2397.
9.
ColhounHMGinsbergHNRobinsonJG, et al.No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY phase 3 studies. Eur Heart J2016; 37: 2981–2989.
10.
SabatineMSLeiterLAWiviottSD, et al.Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol2017; 5: 941–950.
